Q32 Bio Inc. — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Q32 Bio reported Part B SIGNAL-AA trial results for bempikibart in 33 patients with severe/very severe alopecia areata: 40% achieved SALT-20 response (primary endpoint, mean 35.3% SALT score reduction at Week 36), with 44% maintaining SALT-20 during 16-week off-drug follow-up. Safety was favorable with no serious/Grade 3+ adverse events; most common event was injection site reaction (36.3%, mild, self-resolving). Company plans to initiate registration-directed program in H1 2027 pending regulatory meetings in H2 2026.
Why this rating
Pivotal efficacy/safety data validates lead program and clinical pathway for $10.4M-cap biotech; advances toward pivotal trials materially reduces clinical risk and enables value inflection.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-11.2% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $10.20 ▲ 12.58% | at our read · unknown $9.06 | +10 min · unknown $9.52 ▲ 5.02% | +30 min · unknown $9.56 ▲ 5.52% | +1 hr pending | +4 hrs pending |
The stock had already moved -11.18% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.